Flexion Therapeutics, a US-based biotechnology company currently advancing a portfolio of injectable analgesic drug candidates, has sold 5.750 million shares of common stock in their initial public offering (IPO).
The shares were offered at a price of $13 per share for an initial market cap of around $192m.
BMO Capital Markets and Wells Fargo Securities acted as joint book-running managers for the IPO. Flexion trades on the Nasdaq under ticker symbol…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
